Dr. Wim van Hoeve – Managing director
Wim van Hoeve successfully completed both his PhD and MSc degrees in the Physics of Fluids group at the University of Twente. In September 2011 he founded Tide Microfluidics to bring our innovative technique of monodisperse microbubble production to the market.
Dr. Katharine Giannasi – Operations manager
Katharine Giannasi gained her PhD and MPhys degrees at the University of Manchester. Katharine joined the company in December 2012 to strengthen Tide’s product development strategy.
Dr. Peter Frinking – Chief Technical Officer
Peter is a Biomedical physicist with 18+ years’ of experience as a manager and project leader in corporate research and development. He has strong expertise in medical technology and software development within pharmaceutical & medical device companies.
Wouter Bolt – Sales manager
Wouter completed his BSc in Biomedical Engineering at Saxion University in 2008. Since then he has worked in sales for a leading microfluidics manufacturer using his technical knowledge to ensure the products met the customers’ needs. Wouter has 10 years of sales experience in the medical and life science sectors and uses this knowledge to lead the Tide sales efforts.
Want to join the team?
We currently don’t have open vacancies.
If you’re interested in joining the team, either as an employee or intern, then feel free to contact us for an open application: firstname.lastname@example.org
Board of advisors
Prof. Dr. Hessel Wijkstra
Technical University of Eindhoven and Amsterdam Medical Centre
Prof. Dr. Steven Walsh
University of New Mexico
Henne van Heeren MSc
Owner at EnablingMNT
Tide Microfluidics’ vision reflects our strategic ambition and guides our day-to-day activities:
“Everybody should have access to high-quality and affordable healthcare through easy-to-use and accurate medical imaging procedures.”
Tide Microfluidics’ purpose and main objectives are represented by our mission statement:
“Tide Microfluidics improves the efficiency of contrast media, enabling clearer images and more accurate diagnoses. We do this through the use of our innovative microfluidic technology to produce dispersions and emulsions which contain precisely controlled size and narrow size distribution microspheres. We aspire to be a strategic technology partner in the development of products with a better performance and a reduced risk of side effects for the patient.”